Statistical Survey from 1982 to 1991 of 49 Patients with Malignant Melanocytic Tumors
Statistical Survey from 1982 to 1991 of 49 Patients with Malignant Melanocytic Tumors
复制标题
1982年至1991年49例恶性黑素细胞瘤患者的统计调查
DOI：
10.1111/j.1346-8138.1995.tb03426.x
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
H. Yasuno
中科院分区：
文献类型：
--
作者：
E. Ueda;S. Kishimoto;H. Yasuno
我们研究了49例恶性黑色素瘤患者的临床特征和结局：17例肢端雀斑样痣黑色素瘤，14例结节性黑色素瘤，6例浅表扩散性黑色素瘤，1例恶性雀斑样痣黑色素瘤，8例原位黑色素瘤，1例恶性蓝痣，2例不明原因黑色素瘤。在41例无原位黑色素瘤的患者中，34.1%处于I期，17.1%处于II期，48.8%处于III期。没有患者达到IV期。所有I、II和III期黑色素瘤患者均接受广泛切除术、淋巴结清扫术（包括预防性清扫）以及达卡巴嗪、盐酸尼莫司汀和长春新碱（DAV）联合化疗（伴或不伴干扰素-β）。统计学分析显示，肿瘤厚度和浸润程度是与预后显著相关的因素。在登记期间（1982-1991年），每年观察到黑色素瘤新发病例数量逐渐增加;这十年的新发病例数量比前十年增加了约4倍。大多数原发性病变（80.5%）位于上肢或下肢，肿瘤厚度为pT 4的亚组最常见（占所有黑色素瘤的39.0%），浸润水平为IV的最常见（42.5%）。大约一半（51.2%）的黑色素瘤患者为I期或II期;该组的5年生存率为100%。III期患者的5年生存率仅为54.2%（p<0.05）。
We investigated the clinical characteristics and outcome of 49 patients with malignant melanoma: 17 with acral lentiginous melanoma, 14 with nodular melanoma, six with superficial spreading melanoma, one with lentigo maligna melanoma, eight with melanoma in situ, one with malignant blue nevus, and two with melanoma of unknown origin. Of the 41 patients without melanoma in situ, 34.1% were in stage I, 17.1% in stage II, and 48.8% in stage III. No patients had reached stage IV. All patients with stage I, II, and III melanoma were treated with wide resection, lymph node dissection including prophylactic dissection, and combination chemotherapy with dacarbazine, nimustine hydrochloride, and vincristine (DAV) with or without Interferon‐β. The statistical analysis revealed that tumor thickness and level of invasion were factors significantly associated with outcome. A gradual increase in the number of new cases of melanoma was seen each year of the registration period (1982–1991); there was an approximately 4‐fold increase during this decade over the previous decade. The majority of the primary lesions (80.5%) were located on the upper or lower extremities, the pT4 tumor thickness subgroup was the most frequent (39.0% of all melanomas), and invasion level IV was the most common (42.5%). About half (51.2%) of the melanoma patients were stage I or II; this group had a 5‐year survival rate of 100%. The stage III patients had a 5‐year survival rate of only 54.2% (p<0.05).